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Introduction {#phy213841-sec-0001}
============

Heterotrimeric G proteins are coupled to plasma membrane receptors and participate in the regulation of a wide range of cellular functions such as migration, differentiation, proliferation, ion channel activity, and apoptosis (Hilger et al. [2018](#phy213841-bib-0006){ref-type="ref"}; Squires et al. [2018](#phy213841-bib-0018){ref-type="ref"}). In platelets, fundamental elements of the hemostasis machinery, a wide array of cell surface receptors coupled to G proteins mediate their activation (Offermanns [2006](#phy213841-bib-0015){ref-type="ref"}). The P2Y~12~ receptor, an important therapeutic target contributing to purinergic stimulation of platelets, is coupled to heterotrimeric G*α* ~i2~ protein, the predominant G*α* isoform (Gachet [2012](#phy213841-bib-0004){ref-type="ref"}). More recently, G*α* ~i2~ protein was reported to play a thrombo‐inflammatory role in orchestrating thrombus stabilization during hemostasis and mediating tissue damage during experimental cerebral and myocardial ischemia‐reperfusion injury (Devanathan et al. [2015](#phy213841-bib-0003){ref-type="ref"}).

Platelets are activated by a wide range of agonists such as subendothelial collagen, thrombin, ADP secreted from stimulated platelets, and by collagen‐related peptide (CoRP) (Lang et al. [2013](#phy213841-bib-0007){ref-type="ref"}). In the presence of stimulatory signals, platelets degranulate, undergo phospholipid scrambling on their cell membrane, and aggregate to form thrombi that results in vascular blockage (Varga‐Szabo et al. [2009](#phy213841-bib-0020){ref-type="ref"}; Munzer et al. [2014](#phy213841-bib-0013){ref-type="ref"}). Cell membrane scrambling with phosphatidylserine (PS) exposure fosters the assembly of tenase and prothrombinase complexes, and subsequently promoting factor Xa and thrombin generation (Lebois and Josefsson [2016](#phy213841-bib-0009){ref-type="ref"}). In platelets, unconstrained apoptosis has been implicated in thrombocytopenia, bleeding disorders, microparticle shedding as well as affecting their quality during storage (Lebois and Josefsson [2016](#phy213841-bib-0009){ref-type="ref"}; Quach et al. [2018](#phy213841-bib-0016){ref-type="ref"}). PS exposure in apoptotic platelets, triggered by exogenous agents or physiological changes, leads to their clearance from the circulation (Lebois and Josefsson [2016](#phy213841-bib-0009){ref-type="ref"}; Quach et al. [2018](#phy213841-bib-0016){ref-type="ref"}). G*α* ~i2~ has previously been shown to participate in the apoptosis machinery of different cell types (Lopez‐Aranda et al. [2008](#phy213841-bib-0012){ref-type="ref"}; Bissinger et al. [2016](#phy213841-bib-0001){ref-type="ref"}). Despite the recent evidence linking G*α* ~i2~ protein to the execution of thrombosis, its role in platelet survival has hitherto remained elusive. In the present study, using thrombin and collagen‐related peptide (CoRP), an agonist mimicking the effect of contact with collagen and a powerful stimulator of platelet apoptosis (Munzer et al. [2018](#phy213841-bib-0014){ref-type="ref"}), we investigated the influence of G*α* ~i2~ on platelet survival and degranulation ex vivo.

Materials and Methods {#phy213841-sec-0002}
=====================

Mice {#phy213841-sec-0003}
----

Experiments were performed in G*α* ~i2~‐deficient mice (*Gα* ~*i2*~ ^*−/−*^) and their wild‐type (WT) littermates of 10--12 weeks of age. The mice were generated and initially characterized on a SV129 background (Rudolph et al. [1995](#phy213841-bib-0017){ref-type="ref"}). Mice were backcrossed on a C57BL/6 background and kept under specified pathogen‐free (SPF) environment in individually ventilated cages (IVC) to prolong life expectancy (Wiege et al. [2013](#phy213841-bib-0021){ref-type="ref"}; Devanathan et al. [2015](#phy213841-bib-0003){ref-type="ref"}). All animal experiments were conducted according to the German law for the care and use of laboratory animals and were approved by local government authorities (Regierungspräsidium Tübingen according to §4 of 19/12/2011).

Preparation of mouse platelets {#phy213841-sec-0004}
------------------------------

Platelets were obtained from 10‐ to 12‐week‐old mice of either sex which were treated according to the protocol approved by government authorities. Eight hundred *μ*l blood was obtained into tubes containing 200 *μ*l acid‐citrate‐dextrose buffer. Platelet rich plasma (PRP) was obtained by centrifugation at 260 g for 5 min. PRP was then centrifuged at 640 g for 5 min to pellet the platelets. Where necessary, apyrase (0.02 U/mL; Sigma‐Aldrich) and prostaglandin I2 (0.5 *μ*mol/L; Calbiochem) were added to the PRP to prevent activation of platelets during isolation. After two washing steps, the pellet of washed platelets was resuspended in modified Tyrode‐HEPES buffer (pH 7.4, supplemented with 1 mmol/L CaCl~2~). Where indicated, thrombin (0.01 U/mL, Roche, Basel, Switzerland) or collagen‐related peptide (CoRP, 2 *μ*g/mL or 5 *μ*g/mL, kindly provided by R. Farndale, University of Cambridge, Cambridge, UK) were added (Liu et al. [2016](#phy213841-bib-0011){ref-type="ref"}).

Cytosolic calcium {#phy213841-sec-0005}
-----------------

For the measurement of the cytosolic Ca^2+^ concentration, the platelet preparation was washed once in Tyrode buffer (pH 7.4), stained with 3 *μ*mol/L Fluo‐3AM (Biotium, USA) in the same buffer and incubated at 37°C for 30 min. Following the indicated experimental treatment, relative fluorescence was measured utilizing a BD FACS Calibur (BD Biosciences, Heidelberg, Germany) (Towhid et al. [2011](#phy213841-bib-0019){ref-type="ref"}; Liu et al. [2016](#phy213841-bib-0011){ref-type="ref"}).

P‐selectin and activated integrin abundance {#phy213841-sec-0006}
-------------------------------------------

Fluorophore‐labeled antibodies were utilized for the detection of P‐selectin expression (Wug.E9‐FITC, Emfret Analytics, Eibelstadt, Germany) and the active form of *α* ~IIb~ *β*3 integrin (JON/A‐PE, Emfret Analytics, Eibelstadt, Germany). Washed mouse platelets (1x10^6^) were suspended in modified Tyrode buffer (pH 7.4) containing 1 mmol/L CaCl~2~ and antibodies (1:10 dilution) and subsequently subjected to the respective treatments and for the indicated time periods at room temperature (RT). The reaction was stopped by addition of PBS and the samples were immediately analyzed by FACS analysis (Liu et al. [2015](#phy213841-bib-0010){ref-type="ref"}).

Phosphatidylserine exposure and forward scatter {#phy213841-sec-0007}
-----------------------------------------------

Phosphatidylserine exposure was determined in platelets with and without a 10 min thrombin or CoRP treatment (Liu et al. [2016](#phy213841-bib-0011){ref-type="ref"}). To this end, the platelet preparation was centrifuged at 660 g for 5 min followed by washing once with Tyrode buffer (pH 7.4) with 1 mmol/L CaCl~2~, staining with 1:20 dilution of Annexin‐V FITC (ImmunoTools, Germany) in Tyrode buffer (pH 7.4) in the presence of 2 mmol/L CaCl~2~ and incubation at 37°C for 30 min. Annexin‐V binding reflecting surface exposure of phosphatidylserine was evaluated by FACS analysis. In parallel, the forward scatter (FSC) of the platelets was determined by FACS analysis, as a measure of platelet size (Liu et al. [2016](#phy213841-bib-0011){ref-type="ref"}).

Caspase‐3 activity {#phy213841-sec-0008}
------------------

Caspase 3 activity was determined utilizing a CaspGlow Fluorescein Active Caspase‐3 Staining kit from BioVision (CA, USA) according to the manufacturer\'s instruction. Fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 by FACS analysis.

Ceramide abundance {#phy213841-sec-0009}
------------------

Ceramide abundance at platelet cell surface was measured by a monoclonal antibody‐assay. For this purpose, platelets were stained at 37°C for 1 h at a concentration of 1 *μ*g/mL anti‐ceramide antibody (clone MID 15B4, Enzo Life Science GmbH, Lörrach, Germany) in Tyrode buffer at a dilution of 1:10. Platelets were washed once with Tyrode buffer. Subsequently, platelets were stained for 30 min with polyclonal fluorescein isothiocyanate (FITC) conjugated goat anti‐mouse IgG and IgM specific antibody (BD Pharmingen, Hamburg, Germany) at a concentration of 1:50 in Tyrode buffer. Washing of the platelets was performed in order to remove unbound secondary antibody. Finally, the samples were analyzed by flow cytometry at an excitation wavelength of 488 nm and an emission wavelength of 530 nm, as has previously been shown (Gatidis et al. [2010](#phy213841-bib-0005){ref-type="ref"}).

Statistical analysis {#phy213841-sec-0010}
--------------------

Data are shown as means ± SD; n represents the number of independent experiments. All data were tested for significance using ANOVA. *P* \< 0.05 was considered statistically significant.

Results {#phy213841-sec-0011}
=======

This study addressed the impact of G*α* ~i2~ on activation and apoptosis of murine platelets. For this purpose, experiments were performed in mice lacking G*α* ~i2~ and corresponding wild type mice. The platelets were analyzed with or without prior exposure to thrombin (0.01 U/mL) or collagen‐related peptide (CoRP, 2 *μ*g/mL and 5 *μ*g/mL). Individual values (mean ± SD) of female and male WT and G*α* ~i2~‐deficient mice of annexin‐V‐binding, platelet volume, caspase‐3‐positive cells, ceramide abundance, P‐selectin abundance and activated integrin *α* ~IIb~ *β*3 are displayed in Table [1](#phy213841-tbl-0001){ref-type="table"}A--D. No significant differences were observed between male and female WT or G*α* ~i2~‐deficient mice.

###### 

Analyzed parameters in WT and G*α* ~i2~‐deficient mice

  A: Annexin‐V‐binding and forward scatter in WT female and male mice                                                                              
  --------------------------------------------------------------------- -------------- -------------- -------------- -------------- -------------- --------------
  Annexin‐V‐binding \[%\]                                               0.89 ± 0.02    17.07 ± 2.50   19.22 ± 0.87   1.06 ± 0.39    18.22 ± 2.34   18.60 ± 2.75
  Forward Scatter \[Geomean; arb. units\]                               14.95 ± 1.00   10.43 ± 0.95   8.15 ± 0.18    15.09 ± 0.46   11.29 ± 1.03   9.42 ± 1.11

  B: Annexin‐V‐binding and forward scatter in G*α* ~i2~‐deficient female and G*α* ~i2~‐deficient male mice                                                                              
  ---------------------------------------------------------------------------------------------------------- -------------- -------------- -------------- -------------- -------------- --------------
  Annexin‐V‐binding \[%\]                                                                                    1.13 ± 0.17    13.65 ± 0.66   8.75 ± 2.84    1.26 ± 0.53    14.11 ± 0.99   10.32 ± 0.98
  Forward Scatter \[Geomean; arb. units\]                                                                    15.94 ± 0.53   12.04 ± 0.87   11.10 ± 0.86   16.68 ± 0.58   13.30 ± 0.55   11.97 ± 0.46

  C: P‐selectin, activated integrin *α* ~IIb~ *β*3, caspase‐3‐positive cells and ceramide abundance in WT female and WT male mice                                                 
  --------------------------------------------------------------------------------------------------------------------------------- -------------- --------------- -------------- --------------
  P‐selectin \[MFI\]                                                                                                                5.29 ± 0.43    28.01 ± 5.63    5.74 ± 0.39    31.86 ± 3.10
  Activated integrin *α* ~IIb~ *β*3 \[MFI\]                                                                                         5.59 ± 0.27    96.61 ± 15.64   5.29 ± 0.50    88.90 ± 0.83
  Caspase‐3‐positive cells \[%\]                                                                                                    4.65 ± 0.60    21.91 ± 1.65    4.28 ± 0.23    22.69 ± 2.16
  Ceramide abundance \[MFI\]                                                                                                        19.38 ± 2.28   25.48 ± 0.28    21.09 ± 0.08   24.91 ± 3.47

  D: P‐selectin, activated integrin *α* ~IIb~ *β*3, caspase‐3‐positive cells and ceramide abundance in G*α* ~i2~‐deficient female and G*α* ~i2~‐deficient male mice                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- --------------- -------------- ---------------
  P‐selectin \[MFI\]                                                                                                                                                  5.28 ± 0.34    22.98 ± 4.65    5.04 ± 0.23    23.34 ± 7.23
  Activated integrin *α* ~IIb~ *β* \[MFI\]                                                                                                                            5.30 ± 0.13    59.79 ± 16.38   5.44 ± 0.44    44.88 ± 13.68
  Caspase‐3‐positive cells \[%\]                                                                                                                                      4.10 ± 0.13    8.75 ± 1.52     3.95 ± 0.34    9.43 ± 0.80
  Ceramide abundance \[MFI\]                                                                                                                                          19.25 ± 1.44   20.13 ± 2.33    20.54 ± 2.43   20.13 ± 2.02

Annexin‐V‐binding, forward scatter, P‐selectin abundance, activated integrin *α* ~IIb~ *β*3, caspase‐3‐positive cells, and ceramide abundance in female and male WT and G*α* ~i2~‐deficient mice after thrombin and/or CoRP stimulation.

John Wiley & Sons, Ltd

Phosphatidylserine exposure, a hallmark of platelet apoptosis, was quantified by flow cytometry analysis using annexin‐V‐binding as described previously (Cao et al. [2017](#phy213841-bib-0002){ref-type="ref"}). As illustrated in Figure [1](#phy213841-fig-0001){ref-type="fig"}A and D, the percentage of PS‐positive platelets in untreated resting *Gα* ~*i2*~ ^*−/−*^ and WT platelets was not significantly different. Treatment with thrombin and CoRP significantly enhanced the percentage of PS‐positive platelets, an effect significantly less pronounced in *Gα* ~*i2*~ ^*−/−*^ platelets as compared to WT platelets (Fig. [1](#phy213841-fig-0001){ref-type="fig"}B--D). Next, we explored whether G*α* ~i2~‐mediated platelet apoptosis accompanies cell volume alterations (Cao et al. [2017](#phy213841-bib-0002){ref-type="ref"}). As depicted in Figure [1](#phy213841-fig-0001){ref-type="fig"}E and H, forward scatter, reflecting platelet volume, was not significantly different in resting platelets of either genotype but was significantly reduced following thrombin and CoRP treatment, an effect significantly less pronounced in *Gα* ~*i2*~ ^*−/−*^ platelets than in WT platelets (Fig. [1](#phy213841-fig-0001){ref-type="fig"}F--H).

![Gα~i2~ participates in the regulation of platelet cell membrane scrambling and platelet volume. *(*A--C) Original histogram overlays of the annexin‐V binding in platelets isolated from WT mice (blue shadow) and G*α* ~i2~‐deficient mice (black line) without (A) and with (B) a 10 min treatment with thrombin (0.01 U/mL) or (C) a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). (D) Arithmetic means ± SD (*n* = 4) of the annexin‐V binding in platelets isolated from WT mice (blue bar) and G*α* ~i2~‐deficient mice (black bar) prior to (control) and following a 10 min treatment with thrombin (0.01 U/mL) or a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). \#\#\# (*P *\<* *0.001) indicates statistically significant difference from absence of thrombin and CoRP, \* (*P *\<* *0.05) and \*\*\* (*P *\<* *0.001) indicates statistically significant difference from WT mice. (E--G) Original histogram overlays of the forward scatter of platelets isolated from WT mice (blue shadow) and G*α* ~i2~‐deficient mice (black line) without (E) and with (F) a 10 min treatment with thrombin (0.01 U/mL) or (G) a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). (H) Arithmetic means ± SD (*n* = 4) of the forward scatter of platelets isolated from WT mice (blue bar) and G*α* ~i2~‐deficient mice (black bar) prior to (control) and following a 10 min treatment with thrombin (0.01 U/mL) or a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). \#\#\# (*P *\<* *0.001) indicates statistically significant difference from absence of thrombin and CoRP, \* (*P *\<* *0.05) and \*\*\* (*P *\<* *0.001) indicates statistically significant difference from WT mice.](PHY2-6-e13841-g001){#phy213841-fig-0001}

We then sought to elucidate the mechanism(s) regulating G*α* ~i2~‐mediated apoptosis. To this end, we analyzed intracellular Ca^2+^ levels \[Ca^2+^\]~i~ in murine platelets of either genotype using Fluo3 AM fluorescence as described previously (Cao et al. [2017](#phy213841-bib-0002){ref-type="ref"}). As a result, prior to CoRP treatment, \[Ca^2+^\]~i~ in resting platelets was similar in *Gα* ~*i2*~ ^*−/−*^ platelets (22.73 ± 0.69, a.u.; *n* = 10) and in WT platelets (20.95 ± 0.50, a.u.; *n* = 10). Treatment with CoRP was followed by a profound and significant increase of \[Ca^2+^\]~i~ in both *Gα* ~*i2*~ ^*−/−*^ (109.3 ± 1.46, a.u., *n* = 10) and WT platelets (105.9 ± 0.69, a.u.; *n* = 10). The increase following CoRP treatment was, however, not significantly different between the two genotypes, thus, ruling out the involvement of Ca^2+^ signaling in G*α* ~i2~‐mediated platelet apoptosis.

Next, we explored whether other putative mechanisms underpin the regulation of G*α* ~i2~‐mediated platelet apoptosis. To this end, caspase 3 fluorescence (Cao et al. [2017](#phy213841-bib-0002){ref-type="ref"}) was measured and was similar in resting platelets of either genotype (Fig. [2](#phy213841-fig-0002){ref-type="fig"}A and C), but was significantly upregulated after CoRP treatment, an effect which was significantly blunted in *Gα* ~*i2*~ ^*−/−*^ platelets as compared to WT platelets (Fig. [2](#phy213841-fig-0002){ref-type="fig"}B and C).

![Gα~i2~ participates in the regulation of platelet caspase 3 activation and ceramide formation. (A and B) Original histogram overlays of the caspase 3 activity in platelets isolated from WT mice (blue shadow) and G*α* ~i2~‐deficient mice (black line) without (A) and with (B) a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). (C) Arithmetic means ± SD (*n* = 6) of the caspase 3 activity (arbitrary units) in platelets isolated from WT mice (blue bar) and G*α* ~i2~‐deficient mice (black bar) prior to (control) and following a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). ^\#\#\#^ (*P *\<* *0.001) indicates statistically significant difference from absence of CoRP, \*\*\* (*P *\<* *0.001) indicates statistically significant difference from WT mice. (D and E) Original histogram overlays of the ceramide abundance of platelets isolated from WT mice (blue shadow) and G*α* ~i2~‐deficient mice (black line) without (D) and with (E) a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). (F) Arithmetic means ± SD (*n* = 4) of the ceramide abundance of platelets isolated from WT mice (blue bar) and G*α* ~i2~‐deficient mice (black bar) prior to (control) and following a 10 min treatment with collagen‐related peptide CoRP (5 *μ*g/mL). ^\#\#^ (*P *\<* *0.01) indicates statistically significant difference from absence of CoRP, \*\* (*P *\<* *0.01) indicates statistically significant difference from WT mice.](PHY2-6-e13841-g002){#phy213841-fig-0002}

As has previously been shown, hyperosmotic shock triggered a significant increase in platelet annexin‐V‐binding, an effect probably involving ceramide formation (Gatidis et al. [2010](#phy213841-bib-0005){ref-type="ref"}). We thus examined whether ceramide formation is altered in G*α* ~i2~‐deficient platelets as compared to WT platelets. As illustrated in Figure [2](#phy213841-fig-0002){ref-type="fig"}D and F, ceramide abundance was similar in resting platelets. CoRP treatment elicited a significant increase in ceramide abundance in WT platelets as compared to *Gα* ~*i2*~ ^*−/−*^ platelets (Fig. [2](#phy213841-fig-0002){ref-type="fig"}E and F), pointing to the involvement of sphingomyelinase activation in the triggering of G*α* ~i2~‐mediated platelet apoptosis.

We then tested whether G*α* ~i2~ similarly mediates platelet degranulation in response to CoRP. To this end, P‐selectin expression was similar in untreated resting and *Gα* ~*i2*~ ^*−/−*^ platelets (Fig. [3](#phy213841-fig-0003){ref-type="fig"}A and C). Exposure to CoRP significantly increased P‐selectin expression (Cao et al. [2017](#phy213841-bib-0002){ref-type="ref"}) on the platelet surface reflecting enhanced degranulation; this effect was significantly reduced in *Gα* ~*i2*~ ^*−/−*^ platelets as compared to WT platelets (Fig. [3](#phy213841-fig-0003){ref-type="fig"}B and C). Next, we explored whether active integrin *α* ~IIb~ *β*3 is different in the two genotypes. As a result, active integrin *α* ~IIb~ *β*3 was similar in WT and *Gα* ~*i2*~ ^*−/−*^ platelets (Fig. [3](#phy213841-fig-0003){ref-type="fig"}D and F). In addition, CoRP treatment further stimulated active integrin *α* ~IIb~ *β*3 (Cao et al. [2017](#phy213841-bib-0002){ref-type="ref"}) at the platelet surface, an effect that was again significantly attenuated in *Gα* ~*i2*~ ^*−/−*^ platelets (Fig. [3](#phy213841-fig-0003){ref-type="fig"}E and F). Thus, G*α* ~i2~ is dichotomously involved in both platelet degranulation and apoptosis following agonist exposure.

![Gα~i2~ participates in the regulation of platelet degranulation and integrin α~II~ ~b~ *β*3 activation. (A and B) Original histogram overlays of P‐selectin‐related fluorescence reflecting degranulation in platelets isolated from WT mice (blue shadow) and G*α* ~i2~‐deficient mice (black line) without (A) and with (B) a 15 min treatment with collagen‐related peptide CoRP (2 *μ*g/mL). (C) Arithmetic means ± SD (*n* = 6) of the P‐selectin‐related fluorescence (arbitrary units) in platelets isolated from WT mice (blue bar) and G*α* ~i2~‐deficient mice (black bar) prior to (control) and following a 15 min treatment with collagen‐related peptide CoRP (2 *μ*g/mL). ^\#\#\#^ (*P *\<* *0.001) indicates statistically significant difference from absence of CoRP, \* (*P *\<* *0.05) indicates statistically significant difference from WT mice. (D and E) Original histogram overlays of the *α* ~II~ ~b~ *β*3 integrin‐related fluorescence in platelets isolated from WT mice (blue shadow) and G*α* ~i2~‐deficient mice (black line) without (D) and with (E) a 15 min treatment with collagen‐related peptide CoRP (2 *μ*g/mL). (F) Arithmetic means ± SD (*n* = 6) of the *α* ~II~ ~b~ *β*3 integrin‐related fluorescence (arbitrary units) in platelets isolated from WT mice (blue bar) and G*α* ~i2~‐deficient mice (black bar) prior to (control) and following a 15 min treatment with collagen‐related peptide CoRP (2 *μ*g/mL). ^\#\#\#^ (*P *\<* *0.001) indicates statistically significant difference from absence of CoRP, \*\*\* (*P *\<* *0.001) indicates statistically significant difference from WT mice.](PHY2-6-e13841-g003){#phy213841-fig-0003}

Discussion {#phy213841-sec-0012}
==========

Previous studies have shown that the effect of CoRP on degranulation, PS exposure, cell volume, and *α* ~IIb~ *β*3 integrin abundance is mediated, at least in part, by increased \[Ca^2+^\]~i~ (Varga‐Szabo et al. [2009](#phy213841-bib-0020){ref-type="ref"}; Lang et al. [2013](#phy213841-bib-0007){ref-type="ref"}), which is known to trigger platelet activation and stimulate arterial thrombosis (Lang et al. [2013](#phy213841-bib-0007){ref-type="ref"}). Surprisingly, elevation of \[Ca^2+^\]~i~ was similar in platelets of either genotype suggesting that G*α* ~i2~ modifies platelet activation and apoptosis by interfering with mechanisms other than Ca^2+^ entry.

Acid sphingomyelinase degrades membrane sphingomyelin and generates ceramide, which is responsible for cell membrane scrambling and degranulation in a variety of cell types; this lipid signaling is vital in the pathophysiology of several cardiovascular diseases (Lang et al. [2015](#phy213841-bib-0008){ref-type="ref"}). Remarkably, both genetic deficiency and pharmacological inhibition of acid sphingomyelinase has been shown to thwart platelet secretion and PS exposure independently of Ca^2+^ signaling, purportedly due to a signaling defect downstream of phospholipase C activation (Munzer et al. [2014](#phy213841-bib-0013){ref-type="ref"}). Ceramide metabolism further involves ceramidases which has been reported to ameliorate CoRP‐triggered glycoprotein VI‐dependent platelet aggregation and thrombus formation (Munzer et al. [2018](#phy213841-bib-0014){ref-type="ref"}). Along these lines, it is tempting to speculate that PS‐exposure and degranulation of platelets mediated by G*α* ~i2~‐sensitive ceramide generation is a possible mechanism linking previous observations of tissue injury and thrombosis after experimental ischemia‐reperfusion.

In conclusion, the present study sheds light on a novel function of G*α* ~i2~ protein, that is, the regulation of platelet apoptosis, a process, at least in part, mediated by agonist‐sensitive ceramide formation. Our observations on G*α* ~i2~‐mediated platelet survival may have pathophysiological implications in thrombo‐inflammatory conditions. Further investigations are warranted to dissect the relevance of this mechanism in platelet‐related disorders in humans.
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